Previous 10 | Next 10 |
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 PR Newswire NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipelin...
2024-02-22 15:38:13 ET Immunic, Inc. (IMUX) Q4 2023 Earnings Conference Call February 22, 2024, 8:00 AM ET Company Participants Jessica Breu - Vice President, Investor Relations and Communications Daniel Vitt - Chief Executive Officer, President and Director Glen...
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on February 22, 2024 – NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Immunic...
2024-02-13 16:45:29 ET More on Immunic Immunic announces private placement of up to $240 million Seeking Alpha’s Quant Rating on Immunic Read the full article on Seeking Alpha For further details see: Immunic files to sell 55.94M shares for its hol...
Immunic to Participate in Investor and Scientific Conferences in February PR Newswire NEW YORK , Feb. 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...
2024-01-05 10:07:14 ET DENVER, Colo., Jan. 5, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Banzai International Inc (NASDAQ: BNZI), Immunic Inc (NASDAQ: IMUX), Dermata Therapeutics (NASDAQ: DRMA), Aino...
2024-01-05 06:39:23 ET More on Immunic Immunic, Inc. (IMUX) Q3 2023 Earnings Call Transcript Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis Immunic jumps after the bell on positive interim data from phase 2 CALLIPER trial ...
Immunic Highlights 2023 Accomplishments and Upcoming Milestones PR Newswire – Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis , Consistent Across the Entire Progressive Multiple Sclerosis Population and All S...
Immunic, Inc. Announces Private Placement of up to $240 Million PR Newswire NEW YORK , Jan. 5, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a biotechnology company developing a clinical pipeline of orally administered, s...
2023-11-22 16:27:08 ET More on Immunic Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis Immunic jumps after the bell on positive interim data from phase 2 CALLIPER trial Seeking Alpha’s Quant Rating on Immunic For fu...
News, Short Squeeze, Breakout and More Instantly...
Immunic Inc. Company Name:
IMUX Stock Symbol:
NYSE Market:
--News Direct-- Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) in the peer-reviewed journal, Neurology...
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on May 8, 2024 – NEW YORK , May 1, 2024 /PRNewswire/ -- Immunic, ...
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation Immunic Announces Publication of Extended Data From Phase 2 ...